{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:48:37Z","timestamp":1775065717542,"version":"3.50.1"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>All SCD patients need extended RBC antigen typing (by serology or genotyping) for provision of extended RH, K matched blood and to guide RBC selection in those with complex transfusion requirements. Genotyping can also identify <jats:italic>RH<\/jats:italic> variants which can cause sensitisation even when extended RH phenotypically matched blood is provided and alloantibodies associated with <jats:italic>RH<\/jats:italic> variants can cause HTRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To review the use of RBC genotyping in SCD patients at two London trusts (ICHNT, LNWH) with a focus on <jats:italic>RH<\/jats:italic> variants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Retrospective review with data collected from clinical notes, local and national pathology reporting systems.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A 311\/482 (64%) ICHNT patients and 181\/346 (52%) LNWH patients had extended genotyping. Of genotyped patients, 68 (22%) ICHNT and 31 (17%) LNWH patients had <jats:italic>RH<\/jats:italic> variants. Eight ICHNT patients had <jats:italic>RH<\/jats:italic> variants and corresponding antibodies associated with <jats:italic>RH<\/jats:italic> variants; 4\/8 received multiple transfusions with antigen positive RBCs but had no evidence of haemolysis. One LNWH patient had a <jats:italic>RH<\/jats:italic> variant with corresponding alloantibody but could not be investigated further for possible HTR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Most patients (59%) had genotyping and a significant number had <jats:italic>RH<\/jats:italic> variants (99, 20%). A small proportion (9, 9%) had antibodies associated with <jats:italic>RH<\/jats:italic> variants, but with no evidence of clinically significant HTRs despite transfusions in four of them with antigen positive RBCs. All SCD patients should have RBC genotyping including <jats:italic>RH<\/jats:italic> variants (preferentially over extended phenotyping) to guide better selection of RBC units. However, where antigen negative blood cannot be provided, the risk of alloimmunisation is not inevitable and subsequent HTRs from antibodies associated with <jats:italic>RH<\/jats:italic> variants might not always occur.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tme.12838","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T09:05:31Z","timestamp":1638349531000},"page":"210-220","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sickle cell disease patients in two London trusts: Genotyping including <i>RH<\/i> variants"],"prefix":"10.1111","volume":"32","author":[{"given":"Yee Man Tracy","family":"Hui","sequence":"first","affiliation":[{"name":"Haematology Department Imperial College Healthcare NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamala","family":"Gurung","sequence":"additional","affiliation":[{"name":"Haematology Department Imperial College Healthcare NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David Mark","family":"Layton","sequence":"additional","affiliation":[{"name":"Haematology Department Imperial College Healthcare NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercy","family":"Ibidapo","sequence":"additional","affiliation":[{"name":"Haematology Department London North West University Healthcare NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Grimsley","sequence":"additional","affiliation":[{"name":"International Blood Group Reference Laboratory  Bristol UK"},{"name":"Red Cell Immunohaematology NHS Blood and Transplant  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Regan","sequence":"additional","affiliation":[{"name":"Haematology Department Imperial College Healthcare NHS Trust  London UK"},{"name":"Red Cell Immunohaematology NHS Blood and Transplant  UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.7.1431.1431"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.03045.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14346"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16405"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001143"},{"key":"e_1_2_8_7_1","unstructured":"NHSBT Update July.Haemoglobinopathy Genotyping Initiative \u2013 Close of Project;2016.https:\/\/nhsbtdbe.blob.core.windows.net\/umbraco-assets-corp\/14313\/theupdatejuly2016.pdf"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490623"},{"issue":"1","key":"e_1_2_8_9_1","first-page":"373","article-title":"Relevance of RH variants in transfusion of sickle cell patients","volume":"5","author":"Noizat\u2010Pirenne F","year":"2011","journal-title":"Transfusion"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003732"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.178"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.104703"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02382.x"}],"container-title":["Transfusion Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12838","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tme.12838","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tme.12838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T05:12:58Z","timestamp":1692853978000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tme.12838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/tme.12838"],"URL":"https:\/\/doi.org\/10.1111\/tme.12838","archive":["Portico"],"relation":{},"ISSN":["0958-7578","1365-3148"],"issn-type":[{"value":"0958-7578","type":"print"},{"value":"1365-3148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"2021-05-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}